Skip to main content
. 2015 May 10;181(1):87–99. doi: 10.1111/cei.12630

Figure 5.

Figure 5

Effects of protein transduction domain (PTD)-mouse forkhead box protein 3 (mFoxP3) on the development of collagen-induced arthritis (CIA) in DBA/1 mice. Mice were treated with PTD-mFoxP3, mFoxP3 or methotrexate (MTX) on day 22 after chicken type II collagen (CII) immunization at the onset of disease. Attenuated clinical manifestation of arthritis was observed every day. The severity (a) and incidence (b) of arthritis were assessed as described in Materials and methods. Data are expressed as means of the total scores for four limbs or the incidence of arthritis after CII immunization (n = 7–9 per group). PTD-mFoxP3 (0·25 mg/kg) group: day 34 no significance, days 32 and 38 P < 0·05, others P < 0·0001; PTD-mFoxP3 (1·25 mg/kg) group: P < 0·0001; MTX group: P < 0·0001 in (a). (c) Representative joints pathological sections from each group were stained with haematoxylin and eosin (H&E). (a) A normal mouse and (b) a type-II collagen (CII)-immunized mouse. (c) Phosphate-buffered saline (PBS)-treated CIA mouse. (d) MTX treated an established CIA mouse. (e) mFoxP3 protein-treated group. (f,g) 0·25 mg/kg and 1·25 mg/kg PTD-mFoxP3-treated CII-immunized mouse. (d) Histopathological scores for the joints of each group. Data are expressed as the mean ± standard deviation, n = 5, *P < 0·05; **P < 0·01 versus PBS-treated group.